All In Biotech

Drug Trial Radar · NCT00251134

OMEGA-Study: Effect of Omega 3-Fatty Acids on the Reduction of Sudden Cardiac Death After Myocardial Infarction

OMEGA: A Prospective, Randomised, Double-Blind, Placebo-Controlled Multicentre Study in Patients Who Survived Acute Myocardial Infarction to Investigate the Efficacy and Safety of 1 Gram Ω-3-Fatty Acid Ethyl Esters (Ω-3FAE) Daily Versus Placebo to Reduce the Risk of Sudden Cardiac Death.

Last checked: Nov 20, 2026Latest source record: Sep 12, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 3,800 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,800

Actual

Start

Oct 2003

Primary completion

Jun 2008

Study completion Sep 2008

Sponsor

Lead sponsor
Stiftung Institut fuer HerzinfarktforschungAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Trommsdorff GmbH & Co. KG; Pronova BioPharma
First posted
Nov 9, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Cardiovascular disease (CVD) is the leading cause of death in North America and Europe. The major cause of CVD is atherosclerosis like coronary artery disease (CAD). The results of recent trials hint that the course of CAD may be positively influenced by an increased intake of omega 3-fatty acids. The OMEGA-Trial analyses this effect in subjects who suffered an acute myocardial infarction. They are divided into two groups, both receiving standard post-infarction therapy. The subjects of one group additionally receive 1 gram of omega 3-fatty acids daily for a time-period of 12 months, while the subjects in the second group receive 1 gram olive-oil as placebo. Within the period of 12 months all events are reported and used to analyse the efficacy and safety of the additional therapy with omega 3-fatty acids.

Conditions

  • Myocardial Infarction

Interventions

  • Zodin (drug)Drug

    1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months

  • Olive oil (placebo)Drug

    1 gram olive oil daily for a period of 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Sudden cardiac deathTime frame: 12 months

Locations

10 sites in 1 country. Site status is shown where the registry gives one.

  • Johanniter-Krankenhaus Rheinhausen

    Duisburg, Germany

  • Elisabeth-Krankenhaus

    Essen, Germany

  • Staedt. Kliniken Frankfurt/Main-Hoechst

    Frankfurt am Main, Germany

  • Klinikum Fuerth

    Fürth, Germany

  • Universitaetsklinikum Heidelberg

    Heidelberg, Germany

  • Klinikum Ingolstadt

    Ingolstadt, Germany

  • Klinikum Neustadt

    Neustadt/Aisch, Germany

  • Elisabeth-Krankenhaus

    Recklinghausen, Germany

  • Marienkrankenhaus

    Soest, Germany

  • Klinikum der Stadt Ludwigshafen gGmbH

    Ludwigshafen am Rhein, Rhineland-Palatinate, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.